The continuing search for antitumor agents from higher plants

Phytochemistry Letters

Volumn 3, Issue 1, 2010, Pages 1-8

  Pan, Li ^a   Chai, Heebyung ^a   Kinghorn, A Douglas ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anticancer agents; Antineoplastic drug discovery; Compounds in clinical trials; Higher plants; Secondary metabolites

Indexed keywords

14 SUCCINYL TRIPTOLIDE SODIUM SALT; ANTINEOPLASTIC AGENT; BETULIC ACID; BETULIN; CAMPTOTHECIN; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CURCUMIN; EPISILVESTROL; GENISTEIN; HARRINGTONINE; HOMOHARRINGTONINE; INDIGO; INDIRUBIN; LAROTAXEL; MEISOINDIGO; PACLITAXEL; PACLITAXEL POLIGLUMEX; PANDIMEX; PERILLYL ALCOHOL; PHENOXODIOL; PODOPHYLLOTOXIN; PROTOPANAXADIOL; RPR 116278A; SALVICINE; SAPRORTHOQUINONE; SILVESTROL; TRIPTOLIDE; TRIPTOLIDE SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG ISOLATION; DRUG PROGRAM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS; THYROID CARCINOMA; TRADITIONAL MEDICINE; TROPICS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EMBRYOPHYTA;

EID: 77649235468     PISSN: 18743900     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phytol.2009.11.005     Document Type: Review

References (101)

1. Adams T.E., El Sous M., Hawkins B.C., Hirner S., Holloway G., Khoo M.L., Owen D.J., Savage G.P., Scammells P.J., and Rizzacasa M.A. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4′-desmethoxyepisilvestrol. J. Am. Chem. Soc. 131 (2009) 1607-1616
2. Aggarwal B.B., Sundaram C., Malani N., and Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 595 (2007) 1-75
3. Alakurtti S., Mäkelä T., Koskimies S., and Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 29 (2006) 1-13
4. American Cancer Society. Global Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
5. Anonymous. Assay development. Nat. Rev. Drug Disc. 6 (2007) 681
6. Bailey H.H., Attia S., Love R.R., Fass T., Chappell R., Tutsch K., Harris L., Jumonville A., Hansen R., Shapiro G.R., and Stewart J.A. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother. Pharmacol. 62 (2008) 149-157
7. Balunas M.J., and Kinghorn A.D. Drug discovery from medicinal plants. Life. Sci. 78 (2005) 431-441
8. Belanger J.T. Perillyl alcohol: applications in oncology. Altern. Med. Rev. 3 (1998) 448-457
9. Bindseil K.U., Jakupovic J., Wolf D., Lavayre J., Leboul J., and van der Pyl D. Pure compound libraries: a new perspective for natural product based drug discovery. Drug Discov. Today 6 (2001) 840-847
10. Bordeleau M.-E., Robert F., Gerard B., Lindqvist L., Chen S.M.H., Wendel H.G., Brem B., Greger H., Lowe S.W., Porco Jr. J.A., and Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. Clin. Investig. 118 (2008) 1-11
11. Butler M.S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep. 25 (2008) 475-516
12. 2 generation and topoisomerase II inhibition. Free Radic. Biol. Med. 45 (2008) 627-635
13. Cencic R., Carrier M., Galicia-Vázquez G., Bordeleau M.-E., Sukarieh R., Bourdeau A., Brem B., Teodoro J.G., Greger H., Tremblay M.L., Porco Jr. J.A., and Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4 4 (2009) e5223
14. Chabner B.A., Amrein P.C., Druker B.J., Michaelson M.D., Mitsiades C.S., Gross P.E., Ryan D.P., Ramachandra S., Richardson P.G., Supko J.G., and Wilson W.H. In: Brunton L.L., Laso J.S., and Parker K.L. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. (2005), McGraw-Hill, New York 1315-1403
15. Chichewicz R.H., and Kouzi S.A. Chemical, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 24 (2004) 90-114
16. Choueiri T.K., Wesolowski R., and Mekhail T.M. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr. Oncol. Rep. 8 (2006) 104-107
17. ClinicalTrials.gov, 2009a. Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer. Further information available at: http://clinicaltrials.gov/ct2/show/NCT00507429 (accessed October 2009).
18. ClinicalTrials.gov, 2009b. A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Naïve Lung Cancer. Further information available at: http://clinicaltrials.gov/ct2/show/NCT00653939 (accessed October 2009).
19. Constantinou A.I., and Husband A. Phenoxodiol [2H-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)], a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res. 22 (2002) 2581-2585
20. Cooperative Study Group of Phase III Clinical Trial on Meisoindigo, 1997. Phase II clinical trial on meisoindigo in the treatment of chronic myelogenous leukemia. Zhonghua Xueyexue Zazhi 18, 69-72.
21. Corson T.W., and Crews C.M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130 (2007) 769-774
22. Cragg G.M., Boyd M.R., Khanna R., Kneller R., Mays T.D., Mazan K.D., Newman D.J., and Sausville E.A. International collaboration in drug discovery and development: the NCI experience. Pure Appl. Chem. 71 (1999) 1619-1633
23. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), CRC/Taylor & Francis, Boca Raton, FL
24. Cragg G.M., Newman D.J., and Yang S.S. Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J. Nat. Prod. 69 (2006) 488-498
25. Cragg G.M., Grothaus P.G., and Newman D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 109 (2009) 3012-3043
26. Delmonte A., and Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin. Investig. Drugs 18 (2009) 1541-1548
27. Deng B. Direct colorimetric method for determination of indigo and indirubin in Qingdai. Zhong Cao Yao 17 (1986) 163-164
28. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice of Oncology. 8th ed. (2008), Lippincott-Williams & Wilkins, Philadelphia
29. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14 (2008) 4491-4499
30. Eisenbrand G., Hippe F., Jakobs S., and Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol. 130 (2004) 627-635
31. El Sous M., Khoo M.L., Holloway G., Owen D., Scammells P.J., and Rizzacasa M.A. Total synthesis of (-)-silvestrol and (-)-episilvestrol. Angew. Chem. Int. Ed. 46 (2007) 7835-7838
32. Eyberger A.L., Dondapati R., and Porter J.R. Endophytic fungal isolates from Podophyllum peltatum produce podophyllotoxin. J. Nat. Prod. 69 (2006) 1121-1124
33. Fabricant D.S., and Farnsworth N.R. The value of plants used in traditional medicine for drug discovery. Environ. Health Perspect. 109 (2001) 69-75
34. Fidler J.M., Li K., Chung C., Wei K., Ross J.A., Gao M., and Rosen G.D. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2 (2003) 855-862
35. Fischbach M.A., and Walsh C.T. Biochemistry: directing biosynthesis. Science 314 (2006) 603-605
36. Firn R.D., and Jones C.G. Natural products-a simple model to explain chemical diversity. Nat. Prod. Rep. 20 (2003) 382-391
37. Gerard B., Cencic R., Pelletier J., and Porco Jr. J.A. Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew. Chem. Int. Ed. 46 (2007) 7831-7835
38. Hallock Y.F., and Cragg G.M. National Cooperative Drug Discovery Groups (NCDDGs): a successful model for public private partnerships in cancer drug discovery. Pharm. Biol. 41 Suppl. (2003) 78-91
39. Hartwell J.L. Plants Used against Cancer: A Survey (1982), Quarterman, Lawrence, MA
40. Hartwell J.L., and Schrecker A.W. Components of podophyllin. V. The constitution of podophyllotoxin. J. Am. Chem. Soc. 73 (1951) 2909-2916
41. Harvey A.L. Natural products in drug discovery. Drug Discov. Today 13 (2008) 894-901
42. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., and Grever M.R. Life Sci. 57 (1995) 131-141
43. Hwang B.Y., Su B.N., Chai H.-B., Mi Q., Kardono L.B.S., Afriastini J.J., Riswan S., Santarsiero B.D., Mesecar A.D., Wild R., Fairchild C.R., Vite G.D., Rose W.C., Farnsworth N.R., Cordell G.A., Pezzuto J.M., Swanson S.M., and Kinghorn A.D. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 69 (2004) 3350-3358
44. Hwang B.Y., Su B.N., Chai H.-B., Mi Q., Kardono L.B.S., Afriastini J.J., Riswan S., Santarsiero B.D., Mesecar A.D., Wild R., Fairchild C.R., Vite G.D., Rose W.C., Farnsworth N.R., Cordell G.A., Pezzuto J.M., Swanson S.M., and Kinghorn A.D. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 69 (2004) 6156
45. Itokawa H., Wang X., and Lee K.-H. Homoharringtonine and related compounds. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), CRC/Taylor & Francis, Boca Raton, FL 47-70
46. Kantarjian H.M., Talpaz M., Santini V., Murgo A., Cheson B., and O'Brien S.M. Homoharringtonine: history, current research, and future direction. Cancer 92 (2001) 1591-1605
47. Kim S., Salim A.A., Swanson S.M., and Kinghorn A.D. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anti-Cancer Agents Med. Chem. 6 (2006) 319-345
48. King M.L., Chiang C.C., Ling H.C., Fukita E., Ochiai M., and McPhail A.T. X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J. Chem. Soc., Chem. Commun. 20 (1982) 1150-1151
49. Kinghorn A.D. Drug discovery from natural products. In: Lemke R., and Williams D.A. (Eds). Foye's Principles of Medicinal Chemistry. 6th ed. (2008), Walters Kluwer/Lippincott-Williams & Wilkins, Baltimore 12-25
50. Kinghorn A.D., Farnsworth N.R., Soejarto D.D., Cordell G.A., Pezzuto J.M., Udeani G.O., Wani M.C., Wall M.E., Navarro H.A., Kramer R.A., Menendez A.T., Fairchild C.R., Lane K.E., Forenza S., Vyas D.M., Lam K.S., and Shu Y.-Z. Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl. Chem. 71 (1999) 611-1618
51. Kinghorn A.D., Farnsworth N.R., Soejarto D.D., Cordell G.A., Swanson S.M., Pezzuto J.M., Wani M.C., Wall M.E., Oberlies N.H., Kroll D.J., Kramer R.A., Rose W.C., Vite G.D., Fairchild C.R., Peterson R.W., and Wild R. Novel strategies for the discovery of plant-derived anticancer agents. Pharm. Biol. 41 Suppl. (2003) 53-67
52. Kinghorn A.D., Carcache-Blanco E.J., Chai H.-B., Orjala J., Farnsworth N.R., Soejarto D.D., Oberlies N.H., Wani M.C., Kroll D.J., Pearce C.J., Swanson S.M., Kramer R.A., Rose W.C., Fairchild C.R., Emanuel S., Vite G.D., Jarjoura D., and Cope F.O. Discovery of anticancer agents of diverse natural origin. Pure Appl. Chem. 81 (2009) 1051-1063
53. Kiviharju T.M., Lecane P.S., Sellers R.G., and Peehl D.M. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin. Cancer Res. 8 (2002) 2666-2674
54. Koehn F.E., and Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4 (2005) 206-220
55. Li G., Wang Z.H., Sun Y.X., Liu K., and Wang Z. Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin. Pharmacol. Toxicol. 98 (2006) 588-592
56. Li J.H.-W., and Vederas J.G. Drug discovery and natural products: end of an era or an endless frontier?. Science 325 (2009) 161-165
57. Liu G.Y., Bu X., Yan H., and Jia W.W.G. 20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J. Nat. Prod. 70 (2007) 259-265
58. Lucas D.M., Edwards R.B., Lozanski G., West D.A., Shin J.D., Vargo M.A., Davis M.E., Rozewski D.M., Johnson A.J., Su B.N., Goettl V.M., Heerema N.A., Lin T.S., Lehman A., Zhang X.L., Jarjoura D., Newman D.J., Byrd J.C., Kinghorn A.D., and Grever M.R. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113 (2009) 4656-4666
59. Luo C.Y., Tang J.Y., and Wang Y.P. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 9 (2004) 259-270
60. Meng H., Yang C., Jin J., Zhou Y., and Qian W. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk. Lymph. 49 (2008) 1954-1962
61. Meurer-Grimes, B.M., Yu, J., Vairo, G.L., 2004. Therapeutic Compounds and Methods. U.S. Patent 6710075.
62. Mi Q., Pezzuto J.M., Farnsworth N.R., Wani M.C., Kinghorn A.D., and Swanson S.M. Use of the in vivo hollow fiber assay in natural products drug discovery. J. Nat. Prod. 72 (2009) 573-580
63. Miao Z.H., Tang T., Zhang Y.X., Zhang J.S., and Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int. J. Cancer 106 (2003) 108-115
64. Mor G., Fu H.H., and Alvero A.B. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr. Opin. Investig. Drugs 7 (2006) 542-548
65. Newman D.J., and Cragg G.M. Developments and future trends in anticancer natural products drug discovery. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), CRC Taylor & Francis, Boca Raton, FL 553-571
66. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70 (2007) 461-477
67. Neuss N., Gorman M., Boaz H.W., and Cone N.J. Vinca alkaloids. XI. Structures of leurocristine and vincaleukoblastine. J. Am. Chem. Soc. 84 (1962) 1509-1510
68. Noble R.H., Cutts J.H., and Beer C.H. Further biological activities of vincaleukoblastine-an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol. 1 (1958) 347-348
69. PanaGin Pharmaceuticals Inc., 2009. Further information available at: http://www.panagin.com (accessed October 2009).
70. Peffley D.M., Sharma C., Hentosh P., and Buechler R.D. Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells. Arch. Biochem. Biophys. 465 (2007) 266-273
71. Pettit G.R., Cragg G.M., Herald D.L., Schmidt J.M., and Lohavanijaya P. Isolation and structure of combretastatin. Can. J. Chem. 60 (1982) 1374-1376
72. Pettit G.R., Singh S.B., Niven M.L., Hamel E., and Schmidt J.M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of tubulin assembly, derived from Combretum caffrum. J. Nat. Prod. 50 (1987) 119-131
73. Pinney K.G., Jelinek C., Edvardsen K., Chaplin D.J., and Pettit G.R. The discovery and development of the combretastatins. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), CRC Taylor & Francis, Boca Raton, FL 23-46
74. Pisha E., Chai H., Lee I.-S., Chagwedera T.E., Farnsworth N.R., Cordell G.A., Beecher C.W.W., Fong H.H.S., Kinghorn A.D., Brown D.M., Wani M.C., Wall M.E., Heijken T.E., Das Gupta T.K., and Pezzuto J.M. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature (Med.) 1 (1995) 1046-1051
75. Popovich D.G., and Kitts D.D. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch. Biochem. Biophys. 406 (2002) 1-8
76. Potterat O., and Hamburger M. Natural products in drug discovery-concepts and approaches for tracking bioactivity. Curr. Org. Chem. 10 (2006) 899-920
77. Powell R.G., Weisleder D., and Smith C.R. Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J. Pharm. Sci. 61 (1972) 1227-1230
78. Puri S.C., Verma V., Amna T., Qazi G.N., and Spiteller M. An endophytic fungus from Nothapodytes foetida that produces camptothecin. J. Nat. Prod. 68 (2005) 1717-1719
79. Quintas-Cardama A., Kantarjian H., Garcia-Manero G., O'Brien S., Faderl S., Estrov Z., Giles F., Murgo A., Ladie N., Verstovsek S., and Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109 (2007) 248-255
80. Ramgolam V., Ang S.G., Lai Y.H., Loh C.S., and Yap H.K. Traditional Chinese medicines as immunosuppressive agents. Ann. Acad. Med. Singapore 29 (2000) 11-16
81. Raynal N.J.-M., Momparler L., Charbonneau M., and Momparler R.L. Antileukemic activity of genistein, a major isoflavone present in soy products. J. Nat. Prod. 71 (2008) 3-7
82. Saklani A., and Kutty S.K. Plant-derived compounds in clinical trials. Drug Discov. Today 13 (2008) 161-171
83. Sashidhara K.V., White K.N., and Crews P. A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products. J. Nat. Prod. 71 (2009) 588-603
84. Silasi D.-A., Alvero A.B., Rutherford T.J., Brown D., and Mor G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Exp. Opin. Pharmacother. 10 (2009) 1059-1067
85. Singh S. From exotic spice to modern drug?. Cell 130 (2007) 765-768
86. Sneader W. Drug Discovery: A History (2005), John Wiley & Sons Ltd., Chichester, UK
87. Suffness M., and Douros J. Current status of the NCI plant and animal program. J. Nat. Prod. 45 (1982) 1-14
88. Svoboda G.H., Neuss N., and Gorman M. Alkaloids of Vinca rosea (Catharanthus roseus). V. Preparation and characterization of alkaloids. J. Am. Pharm. Soc., Sci. Ed. 48 (1959) 659-666
89. Svoboda G.H. Alkaloids of Vinca rosea (Catharanthus roseus). IX. Extraction and characterization of leurosidine and leurocristine. Lloydia 24 (1961) 173-178
90. Tan G.T., Gylenhaal C., and Soejarto D.D. Biodiversity as a source of anticancer drugs. Curr. Drug Target 7 (2006) 265-277
91. The Rocky Mountain Blood and Marrow Transplant Program (RMBMTP), 2009. Initial Patients Treated in Multinational Phase 2/3 Study of Ceflatonin 09-20-2006. Further information available at: http://www.rockymountainbmt.com/news/Initial-Patients-Treated-in-Multinational-Phase-23-Study-of-Ceflatonin-4682.html (accessed October 2009).
92. U.S. National Institutes of Health, 2009. Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia). Further information available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=494341&version=HealthProfessional&protocolsearchid=3664931 (accessed October 2009).
93. Vuorelaa P., Leinonenb M., Saikkuc P., Tammelaa P., Rauhad J.P., Wennberge T., and Vuorela H. Natural products in the process of finding new drug candidates. Curr. Med. Chem. 11 (2004) 1375-1389
94. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.I., and Sim G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88 (1966) 3888-3890
95. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
96. Xu R.S. Dan-Shen (Salvia miltiorrhiza)-Its Biology and Applications (1990), Science Press, Beijing
97. Yeruva L., Pierre K.J., Elegbede A., Wang R.C., and Carper S.W. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett. 257 (2007) 216-226
98. Young S.L., and Chaplin D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs 13 (2004) 171-1182
99. Zhang J.-S., Ding J., Tang Q.-M., Li M., Zhao M., Lu L.-J., Chen L.-J., and Yuan S.-T. Synthesis and antitumor activity of novel diterpene quinone salvicine and the analogs. Bioorg. Med. Chem. Lett. 9 (1999) 2731-2736
100. Zhongyaoshijia, 2009. Further information available at: http://www.zysj.com.cn/zhongyaocai/yaocai_q/qingdai.html#399 (accessed October 2009).
101. Zuo M., Li Y., Wang H., Zhou J., Li H., Liu H., Liu H., Xin H., Zhang S., and Chen X. The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo. J. Chemother. 20 (2008) 728-733